AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04723355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An innovative 3-lead wireless water resistant Holter device
Description: The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
Study NCT04723355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A conventional device
Description: The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
Study NCT04790734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation drugs
Description: Different sedation drugs
Study NCT04790734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedation drugs
Description: Different sedation drugs
Study NCT06136910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
Description: 1. Recombinant human adenovirus type 5 injection : 21 days is one treatment cycle, in principle, 4 cycles of administration, 1 injection on day 1 (d1) of each cycle; the number of injections is determined according to the patient's tolerance and the ease of operation of the injection site, no less than 2 times.~2. tirelizumab: 200mg intravenous, d1, Q21d, administered until disease progression or intolerable side effects occur~3. platinum-containing two-drug chemotherapy: adenocarcinoma, pemetrexed combined with carboplatin, 4-6 cycles, d2, Q21d; non-adenocarcinoma, paclitaxel/gemcitabine combined with carboplatin, 4-6 cycles, d2, Q21d.
Study NCT05298410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limitless
Description: Participants will be instructed to take Limitless for 30 days.
Study NCT06394297 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT to reproduce HDR BT dose distribution in non-operated patients LACC
Study NCT04711044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papain
Description: Papain will be applied using cowhage spicules inactivated by heat
Study NCT04711044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied
Study NCT04711044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
Study NCT04711044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-menthol
Description: A 1 mL aliquot is dispensed onto a 2,5 × 2,5 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape.
Study NCT04988087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHV370
Description: MHV370 for 24 weeks
Study NCT04988087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 24 weeks
Study NCT05822258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk under 3 conditions (normal, physical tasks, verbal tasks)
Description: Each patient will have 2 visits :~* First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~* A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~* Normal condition without addition of additional physical and verbal tasks~* Condition with added physical tasks: The physical task of holding a ball in the center of a tray~* Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions.
Study NCT06634017 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Platelet rich fibrin
Description: Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
Study NCT06634017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
Study NCT06437574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vytorin
Description: Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.
Study NCT06437574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe is a drug that targets one of the primary sources of cholesterol, absorption in the gut.
Study NCT04820530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan (LNP023)
Description: Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral
Study NCT05597735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecovirimat
Description: The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~* 25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~* 40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.
Study NCT05597735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
Study NCT06504849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving LSM messages.
Description: * LSM messages via instant messaging applications~* Chat-type support messages via instant messaging applications
Study NCT06504849 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Receiving brief pre-HTN messages.
Description: * A flyer with brief pre-HTN information which is distributed during the recruitment phase~* Brief pre-HTN messages via instant messaging applications
Study NCT04878848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Exercises
Description: Within the scope of proprioceptive neuromuscular facilitation exercises, rhythmic initiation, repeated stretch and hold-relax techniques in the upper extremity flexion-abduction-external rotation pattern and scapular patterns of anterior elevation, posterior depression, anterior depression and posterior elevation will be applied to the participants. In addition to these exercises, functional activities in the flexion-abduction-external rotation pattern such as hair combing, turning over from side lying, wearing a jacket, reaching on the shelf will be performed.
Study NCT04878848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation Group
Description: Active assisted / active range of motion exercises and Wand exercises will be applied to the participants in the conventional rehabilitation group for flexion, abduction and external rotation movements. Exercises will be applied as 5 repetitions in the first 2 weeks and 10 repetitions in the last 2 weeks. Strengthening exercises will be performed with an elastic band and free weights. Strengthening exercises will be started as 2 sets of 5 repetitions and at the end of the second week, it will be applied as 2 sets of 10 repetitions. In addition to these exercises, glenohumeral distraction, glenohumeral posterior and caudal glide will be applied for joint mobilization and it will show progression at the end of the second week.
Study NCT06453135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: On the Day 0, participants received a single dose of eculizumab before the transplant surgery: 900 mg (blood type antibody titer ≥ 1:64 and/or body weight ≥ 60 kg) or 600 mg (blood type antibody titer \< 1:64 and body weight \< 60 kg). Plasmapheresis was not planned. When participants developed AMR, they may receive additional dose of eculizumab.
Study NCT05336383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Given by Infusion
Study NCT05312320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information film
Description: * Sexual activity after MI does not increase risk of recurrence or death~* Sexual activity is associated with improved outcome after MI~* Resuming sexual activity as normal is recommended and completely safe
Study NCT06462560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vivo Online Exercise Program
Description: Virtual online exercise programs conducted by the Vivo team consisting of multiple time a week group live programs
Study NCT06462560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medbridge Home program
Description: At home exercise program accessed through exercise descriptions and short vidoes
Study NCT06370650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma, narrow band UVB
Description: Role of PRP in treating stable vitiligo
Study NCT04698460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid coronary revascularization
Description: A staged procedure with a minimally invasive direct coronary artery bypass grafting of left anterior descending artery by left internal mammary artery (LIMA-LAD MIDCAB) at first stage, and percutaneous stenting of iFR-significant lesions in non-LAD arteries at the second stage
Study NCT05102344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Social Skills Training
Description: Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation.
Study NCT05102344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Intervention
Description: Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation accompanied by trained therapy dogs
Study NCT04698460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Description: A conventional procedure of median thoracotomy with on-pump bypass grafting of left anterior descending artery by left internal mammary artery and saphenous vein grafting of circumflex and/or right coronary artery
Study NCT05363618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)
Description: Active study product
Study NCT05363618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1.4 ml
Description: Placebo
Study NCT06296043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Exercise Group
Description: Exercise Group
Study NCT06296043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Su-Jok Intervention
Description: Hand massage with seeds
Study NCT06412640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keverprazan
Description: Potassium-competitive acid blocker
Study NCT06412640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keverprazan
Description: Potassium-competitive acid blocker
Study NCT06412640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT06412640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT06247475 — intervention group
Intervention type: OTHER
Intervention: Answers generated by ChatGPT
Description: Participants will assign a satisfaction score based on the appropriateness of each answer.
Study NCT06089863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAMPERO program
Description: This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow :~* 5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object~* 5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority~* 1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick~* 2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture~* 2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation
Study NCT06169787 — intervention group
Intervention type: PROCEDURE
Intervention: sentinel lymph node biopsy
Description: sentinel lymph node biopsy
Study NCT06169787 — intervention group
Intervention type: PROCEDURE
Intervention: comprehensive pelvic lymphadenectomy
Description: comprehensive pelvic lymphadenectomy
Study NCT05672641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inertial training
Description: Inertial training group performed their training three times a week (Monday, Wednesday, and Friday) between between 7:00 a.m. and 8:30 a.m. for 6 weeks. Participants performed inertial training using Cyklotren (Inerion, Poland). Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
Study NCT05672641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body building training
Description: Body building group performed body building training three times a week (Monday, Wednesday, and Friday) between 7:00 a.m. and 8:30 a.m. for 6 weeks using free weights. Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
Study NCT05961241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: runnin training program
Description: gradual training program
Study NCT05961241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: runnin training program
Description: gradual training program
Study NCT04908384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Asthma Care Together (IMPACT)
Description: IMPACT is a novel health application and wearable device
Study NCT05406739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test Meals
Description: For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute \[60 kcal\]; 2 slices of bread \[120 kcal\] with 30 g strawberry jam \[75 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute \[120 kcal\]; 4 slices of bread \[240 kcal\] with 60 g strawberry jam \[150 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water.
Study NCT05406739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Meals
Description: For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute \[60 kcal\]; 2 slices of bread \[120 kcal\] with 30 g strawberry jam \[75 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute \[120 kcal\]; 4 slices of bread \[240 kcal\] with 60 g strawberry jam \[150 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water.
Study NCT06174012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride
Description: Sodium fluoride was applied before radiotherapy, at 3 months, 6 months, and 12 months after radiotherapy.
Study NCT05805904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days.
Study NCT05956327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic Endurance Training
Description: Aerobic endurance training on a bicycle ergometer (week 1 to 6: three units per week á 40 minutes, week 7 to 12: three units á 45 minutes, in groups of up to three patients over 13 weeks)
Study NCT05956327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility, strengthening and balance training
Description: Flexibility, strengthening and balance training (exercises from the areas of stretching, strength, balance and relaxation, 3x40 min from week 1-2, 3x45 min from week 3-4 and 3x50 min from week 5-13, in groups of up to three patients over 13 weeks)
Study NCT05805904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT05090631 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Description: GWAS
Study NCT05502094 — intervention group
Intervention type: OTHER
Intervention: Heart Rate Variability Measurement
Description: The heart rate variability of the participants will be measured with the Polar H10 device with a measurement time of 5 minutes.
Study NCT04741204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release Oral Tablet
Description: initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.
Study NCT06290531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy device (cold and vibration)
Description: The device produces cold and vibration to act on the gate control theory and provide painless injection by nerve distraction
Study NCT06290531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy device (vibration only)
Description: The device produces vibration to act on the gate control theory and provide painless injection by nerve distraction
Study NCT06290531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: precooling
Description: Ice cubes used for applying coolness at the injection area
Study NCT06038695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB
Description: * Fibro-Gide is the Volume-Stable Collagen Matrix.~* Recombinant human platelet-derived growth factor-BB will be found within the device of GEM21S.
Study NCT06463249 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CORE Helpline
Description: All participants will receive the Core Helpline program (CORE) for 2 months, which includes written weight loss material, use of a smartphone app, weekly text messages and email reminders and 1 optional participant-initiated coaching call per month.
Study NCT06089434 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography (TEE) with limited number of TEE clips
Description: The intervention group would be limited to fewer than 20 TEE clips per case (versus the average of \~ 80-100 TEE clips per case).
Study NCT06089434 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist
Description: The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.
Study NCT06170723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days